Outlook Therapeutics Inc. (NASDAQ:OTLK) finished Thursday with a subtraction of $0.0 to close at $1.61, an upside of 0.10 percent. An average of 860,006 shares of common stock have been traded in the last five days. There was a fall of -$0.0150 in the past week, and it reached a new high 14 times over the past 12 months. The last 20 days have seen an average of 1,000,897 shares traded, while the 50-day average volume stands at 1,336,721.
OTLK stock has decreased by -8.43% in the last month. The company shares reached their 1-month lowest point of $1.5800 on 08/07/23. With the stock rallying to its 52-week high on 06/06/23, shares of the company touched a low of $0.80 and a high of $2.03 in 52 weeks. It has reached a new high 11 times so far this year and achieved 49.22% or $0.5350 in price. In spite of this, the price is down -20.61% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
OTLK stock investors should be aware that Outlook Therapeutics Inc. (OTLK) stock had its last reported insider trading activity 113 days ago on Apr 20. In this transaction, the insider spent $590,200. Chief Commercial Officer, Evanson Jeff, disposed of 267,000 shares at a price of $1.11 on Jan 20. The insider now owns more than $296,370 worth of shares. Prior to that, Chief Commercial Officer Evanson Jeff went on to Sale 103,255 shares at $1.22 each on Jan 19. An amount of $125,971 was transacted.
Valuation Metrics
Outlook Therapeutics Inc. (OTLK) stock’s beta is 0.67. Other valuation ratios to consider include the price-to-book (PB) ratio at 40.29.
Financial Health
The quick ratio of Outlook Therapeutics Inc. for the three months ended March 30 was 1.20, and the current ratio was 1.20, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 3.03 for the quarter ending March 30. Its gross profit as reported stood at $63.07 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Outlook Therapeutics Inc.’s return on assets was -124.50%.
Earnings Surprise
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$6.65 million in the quarter, while revenues of -$18.66 million were shrunk -196.24%. The analyst consensus anticipated Outlook Therapeutics Inc.’s latest quarter earnings to come in at -$0.06 per share, but it turned out to be -$0.03, a 50.00% surprise. For the quarter, EBITDA amounted to -$6.83 million. Shareholders own equity worth $256.67 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Outlook Therapeutics Inc. (OTLK) price momentum. RSI 9-day as of the close on 10 August was 42.15%, suggesting the stock is Neutral, with historical volatility in this time frame at 23.18%.
As of today, OTLK’s price is $1.6350 -0.92% or -$0.0150 from its 5-day moving average. OTLK is currently trading -2.12% lower than its 20-day SMA and +56.80% higher than its 100-day SMA. However, the stock’s current price level is +7.67% above the SMA50 and +39.22% above the SMA200.
The stochastic %K and %D were 25.31% and 28.24%, respectively, and the average true range (ATR) was 0.0803. With the 14-day stochastic at 21.87% and the average true range at 0.0872, the RSI (14) stands at 45.67%. The stock has reached -0.0200 on the 9-day MACD Oscillator while the 14-day reading was at -0.0244.
Analyst Ratings
CapitalOne launched coverage on Outlook Therapeutics Inc. (NASDAQ: OTLK) in its analyst report released on July 13, 2023. The firm assigned the stock an Overweight rating. The consensus rating for Outlook Therapeutics Inc. (OTLK) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell OTLK, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 7 others rate it as a “buy”.
What is OTLK’s price target for the next 12 months?
Analysts predict a range of price targets between $4.50 and $10.00, with a median target of $6.00. Taking a look at these predictions, the average price target given by analysts for Outlook Therapeutics Inc. (OTLK) stock is $6.50.
